Celcuity Reports Phase 3 Success for Gedatolisib in Breast Cancer
MINNEAPOLIS, MINNESOTA, May 01, 2026 Celcuity has announced positive topline results from its Phase 3 VIKTORIA-1 trial, demonstrating a...
Breast Cancer
Advertisement
Arvinas Inc Gains FDA Approval for VEPPANU PROTAC Drug
NEW HAVEN, Conn., May 1, 2026 Arvinas, Inc., in collaboration with Pfizer Inc., announced that the U.S. Food and...
Marengo Reports Phase 2 Breast Cancer Data at AACR
CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics, Inc. announced late-breaking Phase 2 clinical results for its investigational immunotherapy invikafusp...
Adagene Reports Strong Muzastotug KEYTRUDA CRC Data
San Diego, USA & Suzhou, China, April 2, 2026 Strong Clinical Efficacy in MSS Colorectal Cancer In a major...
IDEAYA Biosciences Doses First Patient in IDE574 Trial
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
Advertisements
Henlius Secures NMPA IND for HLX319 Breast Cancer Drug
SHANGHAI, China, April 1, 2026 Shanghai Henlius Biotech, Inc. announced that the China National Medical Products Administration (NMPA) has...
Novartis $3B Oncology Deal with Synnovation to Boost Breast Cancer Pipeline
BASEL, Switzerland, March 20, 2026 Novartis announced a major strategic acquisition to strengthen its oncology portfolio, agreeing to acquire...
Pfizer Reports Positive Phase 2 Breast Cancer Results
New York, USA | March 17, 2026 Pfizer has announced positive topline results from its Phase 2 FOURLIGHT-1 clinical...
Guardant Unveils New Multiomic Liquid Biopsy Insights at SABCS 2025
PALO ALTO, CA — December 5, 2025 — Guardant Health announced it will present 14 abstracts at the 2025...
BriaCell Reveals New Phase 2 and Phase 3 Data Ahead of SABCS 2025
Philadelphia, PA and Vancouver, BC — December 2, 2025 — BriaCell Therapeutics Corp. announced plans to present three major...
Advertisement
